Filtered By:
Condition: Cholesterol

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 8092 results found since Jan 2013.

Previous Statin Use and High-Resolution Magnetic Resonance Imaging Characteristics of Intracranial Atherosclerotic Plaque: The Intensive Statin Treatment in Acute Ischemic Stroke Patients With Intracranial Atherosclerosis Study Clinical Sciences
Conclusions— Premorbid statin usage is independently associated with reduced plaque enhancement and a decrease in large cortical lesions in patients with intracranial atherosclerotic stroke.
Source: Stroke - June 26, 2016 Category: Neurology Authors: Chung, J.-W., Hwang, J., Lee, M. J., Cha, J., Bang, O. Y. Tags: Lipids and Cholesterol, Magnetic Resonance Imaging (MRI), Treatment, Cerebrovascular Disease/Stroke, Ischemic Stroke Clinical Sciences Source Type: research

The Neurorestorative Benefit of GW3965 Treatment of Stroke in Mice Original Contributions
Conclusions— These data indicate, for the first time, that GW3965 promotes synaptic protein expression and axonal growth and increases vascular remodeling, which may contribute to improvement of functional outcome after stroke. Increasing Angiopoietin-1/Tie2 signaling activity may play an important role in GW3965-induced brain plasticity and neurological recovery from stroke.
Source: Stroke - December 24, 2012 Category: Neurology Authors: Cui, X., Chopp, M., Zacharek, A., Cui, Y., Roberts, C., Chen, J. Tags: Pathology of Stroke, Other Stroke Treatment - Medical, Transient Ischemic Attacks Original Contributions Source Type: research

Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease: The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) Trial Major Clinical Trials
Conclusions— Although there were numerically more ischemic strokes with addition of ERN to simvastatin that reached nominal significance, the number was small, and multivariable analysis accounting for known risk factors did not support a significant association between niacin and ischemic stroke risk. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00120289.
Source: Stroke - September 23, 2013 Category: Neurology Authors: Teo, K. K., Goldstein, L. B., Chaitman, B. R., Grant, S., Weintraub, W. S., Anderson, D. C., Sila, C. A., Cruz-Flores, S., Padley, R. J., Kostuk, W. J., Boden, W. E., on behalf of the AIM-HIGH Investigators Tags: Secondary prevention, Risk Factors, Acute Cerebral Infarction, Other Stroke Treatment - Medical Major Clinical Trials Source Type: research

Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial Clinical Sciences
Conclusions— This post hoc analysis suggests that atorvastatin treatment may improve renal function in patients with prior stroke or transient ischemic attack with and without chronic kidney disease, and that atorvastatin treatment may prevent eGFR decline in patients with stroke and diabetes mellitus. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00147602.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Amarenco, P., Callahan, A., Campese, V. M., Goldstein, L. B., Hennerici, M. G., Messig, M., Sillesen, H., Welch, K. M. A., Wilson, D. J., Zivin, J. A. Tags: Lipids, Secondary prevention, Cerebrovascular disease/stroke Clinical Sciences Source Type: research

D-4F Decreases White Matter Damage After Stroke in Mice Basic Sciences
Conclusions— D-4F treatment initiated 2 h after MCAo decreases neuroinflammation and white matter damage and improves functional outcome after stroke. D-4F-induced increase in IGF1 may contribute to D-4F–induced neurite/axonal outgrowth after stroke.
Source: Stroke - December 28, 2015 Category: Neurology Authors: Cui, X., Chopp, M., Zacharek, A., Cui, C., Yan, T., Ning, R., Chen, J. Tags: Treatment, Ischemic Stroke Basic Sciences Source Type: research

Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke Clinical Sciences
Conclusions—Elevated Lp(a) levels are associated with a higher risk for combined vascular event recurrence in patients with acute, first-ever ischemic stroke. This finding should be validated in larger, multicenter trials.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01378468.
Source: Stroke - December 22, 2016 Category: Neurology Authors: Kristin S. Lange, Alexander H. Nave, Thomas G. Liman, Ulrike Grittner, Matthias Endres, Martin Ebinger Tags: Lipids and Cholesterol, Cardiovascular Disease, Risk Factors, Secondary Prevention, Ischemic Stroke Original Contributions Source Type: research

Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke Clinical Sciences
Conclusions—Our randomized trial involving patients with acute ischemic stroke and dyslipidemia did not show any superiority of early statin therapy within 24 hours of admission compared with delayed statin therapy 7 days after admission to alleviate the degree of disability at 90 days after onset.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02549846.
Source: Stroke - October 23, 2017 Category: Neurology Authors: Shinichi Yoshimura, Kazutaka Uchida, Takashi Daimon, Ryuzo Takashima, Kazuhiro Kimura, Takeshi Morimoto, on behalf of ASSORT Trial Investigator* Tags: Clinical Studies, Lipids and Cholesterol, Treatment, Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Trends in Risk Factor Prevalence and Management Before First Stroke: Data From the South London Stroke Register 1995-2011 Clinical Sciences
Conclusions— Antiplatelet and cholesterol-lowering treatment prescribing have improved significantly over time; however, only a minority with AF received anticoagulants, and this did not improve significantly. Overall, 30% of strokes occurred in patients with previously diagnosed but untreated risk factors.
Source: Stroke - June 24, 2013 Category: Neurology Authors: Marshall, I. J., Wang, Y., McKevitt, C., Rudd, A. G., Wolfe, C. D. A. Tags: Primary prevention, Anticoagulants, Antiplatelets, Other Stroke Treatment - Medical, Epidemiology Clinical Sciences Source Type: research

Point-of-Care Cluster Randomized Trial in Stroke Secondary Prevention Using Electronic Health Records Clinical Sciences
Conclusions— Large pragmatic intervention studies may be implemented at low cost by using electronic health records. The intervention used in this trial was not found to be effective, and further research is needed to develop more effective intervention strategies. Clinical Trial Registration— URL: http://www.controlled-trials.com. Current Controlled Trials identifier: ISRCTN35701810.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Dregan, A., van Staa, T. P., McDermott, L., McCann, G., Ashworth, M., Charlton, J., Wolfe, C. D. A., Rudd, A., Yardley, L., Gulliford, M. C., Meredith, Kerry, Murray, Mant, Robson, Haywood, Pursani Tags: Other Stroke Treatment - Medical Clinical Sciences Source Type: research

Functional Gain After Inpatient Stroke Rehabilitation: Correlates and Impact on Long-Term Survival Brief Reports
Conclusions— Several factors are independently associated with functional gain after SR. Our findings strongly suggest that the magnitude of functional improvement is a powerful predictor of long-term mortality in patients admitted for SR.
Source: Stroke - September 28, 2015 Category: Neurology Authors: Scrutinio, D., Monitillo, V., Guida, P., Nardulli, R., Multari, V., Monitillo, F., Calabrese, G., Fiore, P. Tags: Other Stroke Treatment - Medical Brief Reports Source Type: research

Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients Clinical Sciences
Background and Purpose—We sought to determine whether folic acid supplementation can independently reduce the risk of first stroke associated with elevated total cholesterol levels in a subanalysis using data from the CSPPT (China Stroke Primary Prevention Trial), a double-blind, randomized controlled trial.Methods—A total of 20 702 hypertensive adults without a history of major cardiovascular disease were randomly assigned to a double-blind daily treatment of an enalapril 10-mg and a folic acid 0.8-mg tablet or an enalapril 10-mg tablet alone. The primary outcome was first stroke.Results—The median treatment durat...
Source: Stroke - October 23, 2016 Category: Neurology Authors: Qin, X., Li, J., Spence, J. D., Zhang, Y., Li, Y., Wang, X., Wang, B., Sun, N., Chen, F., Guo, J., Yin, D., Sun, L., Tang, G., He, M., Fu, J., Cai, Y., Shi, X., Ye, P., Chen, H., Zhao, S., Chen, M., Gao, C., Kong, X., Hou, F. F., Huang, Y., Huo, Y. Tags: Clinical Studies, Diet and Nutrition, Primary Prevention, Hypertension, Ischemic Stroke Original Contributions Source Type: research

Adherence to Hospital Discharge Medication in Patients With Ischemic Stroke: A Prospective, Interventional 2-Phase Study Brief Reports
Conclusions— Providing detailed information on medication changes can lead to substantially improved adherence to discharge medication, probably resulting in better secondary stroke prevention.
Source: Stroke - January 18, 2013 Category: Neurology Authors: Hohmann, C., Neumann-Haefelin, T., Klotz, J. M., Freidank, A., Radziwill, R. Tags: Compliance/Adherence, Secondary prevention, Cerebrovascular disease/stroke, Anticoagulants, Antiplatelets Brief Reports Source Type: research

Community-Based Intervention to Improve Cardiometabolic Targets in Patients With Stroke Clinical Sciences
Conclusions—The intervention in this largely negative trial only had a detectable effect on attaining target for lipids but not for other factors at 12 months or any factor at 24 months. This limited effect may be attributable to inadequate uptake of behavioral/lifestyle interventions, highlighting the need for new or better approaches to achieve meaningful behavioral change.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: ACTRN12608000166370.
Source: Stroke - August 28, 2017 Category: Neurology Authors: Muideen T. Olaiya, Dominique A. Cadilhac, Joosup Kim, Mark R. Nelson, Velandai K. Srikanth, Richard P. Gerraty, Christopher F. Bladin, Sharyn M. Fitzgerald, Thanh Phan, Judith Frayne, Amanda G. Thrift Tags: Lifestyle, Risk Factors, Secondary Prevention, Treatment, Cerebrovascular Disease/Stroke Original Contributions Source Type: research

Risk Factors, Stroke Prevention Treatments, and Prevalence of Cerebral Microbleeds in the Framingham Heart Study Brief Reports
Conclusions— We observed the expected association of hypertension with deep CMB and low cholesterol and APOE 4 with lobar CMB. In addition, statin use was independently associated with CMB risk. This potential adverse effect of statin use needs to be examined in other cohorts.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Romero, J. R., Preis, S. R., Beiser, A., DeCarli, C., Viswanathan, A., Martinez-Ramirez, S., Kase, C. S., Wolf, P. A., Seshadri, S. Tags: Risk Factors for Stroke, Epidemiology Brief Reports Source Type: research

Seladin-1/DHCR24 Is Neuroprotective by Associating EAAT2 Glutamate Transporter to Lipid Rafts in Experimental Stroke Basic Sciences
Conclusions— These results support the idea that lipid raft integrity, ensured by seladin-1/DHCR24, plays a crucial protective role in the ischemic brain by guaranteeing EAAT2-mediated uptake of glutamate excess.
Source: Stroke - December 28, 2015 Category: Neurology Authors: Hernandez-Jimenez, M., Martinez-Lopez, D., Gabande-Rodriguez, E., Martin-Segura, A., Lizasoain, I., Ledesma, M. D., Dotti, C. G., Moro, M. A. Tags: Cerebrovascular Disease/Stroke, Neuroprotectants Basic Sciences Source Type: research